Laissez-faire in clinical research has unleashed a ruthless profit-making machine blind to notions of justice or equity. It is time to rein in Big Pharma
IN EARLY 2012, a promising experimental antidepressant failed to make any impression on American patients in last-stage trials, forcing its developer, a small US drug company called Targacept, to call off further research on the drug. The fiasco came as an unexpected shock especially as the drug, labelled TC-5214, had earlier passed with flying colours in trials on Indian patients.
As Targacept and AstraZeneca, the Anglo-Swedish pharma giant that had agreed to pay as much as US $1.24 billion for exclusive rights to the drug, cursed their luck and licked their wounds, the episode raised fresh stink about the murkiness surrounding clinical trials. In an angry article for thestreet.com, Adam Feuerstein, a much-respected enfant terrible of the drug industry, put the entire blame for the Targacept disaster on offshore trials: “Never trust clinical data from India. Clinical trials conducted in Russia aren’t any more credible, so don’t trust data from there either.”
He might have added to the rogue gallery more countries from Asia and Eastern Europe, like China, Bangladesh, Poland, and Ukraine, which have become hotbeds of clinical trials for Western drug companies in the past two decades. Reliable data on offshore trials are notoriously hard to get because drug companies are not required to report them, but just to give you some idea about the offshore clinical trial mushroom, according to the US Department of Health and Human Services, the number of trials for drugs meant for the American market rose from a modest 271 in 1990 to a staggering 6,485 in 2008, a spike of over 2,000 per cent! And early in September, an investigation by an online health paper called statnews.com revealed that 90 per cent of new US drugs approved this year were tested at least in part outside the US and Canada.
This story is from the October 1, 2017 edition of Down To Earth.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the October 1, 2017 edition of Down To Earth.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
THE ALCHEMY OF EMOTIONS - SL'OTH
As with all personality traits, laziness is a combination of genes and environment
THE AL'CHEMY OF EMOTIONS - WRATH
Anger is an emotional programme, a part of natural selection that helps us bargain for better treatment
THE AL'CHEMY OF EMOTIONS - GLUTTONY
We have been captured by food and it is driving us to do something that is arguably not good for us
THE AL'CHEMY OF EMOTIONS - ENVY
Envy gives people a fundamental desire for a higher social rank
THE AL'CHEMY OF EMOTIONS-L'UST
Love, lust, attachments are basic brain circuits. They are too primitive a system and will never change
THE AL'CHEMY OF EMOTIONS - GREED
Evolutionary biology sees greed as a way to increase your chances of survival
THE AL'CHEMY OF EMOTIONS
I felt for the tormented whirlwinds Damned for their carnal sins Committed when they let their passions rule their reason
INVISIBLE THREAT
Significant presence of microplastics in Puducherry’s agricultural soil raises concerns for soil and crop health
Feeding off each other
VEGETARIAN MOVEMENTS IN SOUTH ASIA AND THE WEST GREW WITH MUTUAL SUPPORT AND VALIDATION
India's unhealthy patent amendments
Despite strong pleas, the Modi regime has changed the rules to impose a cost on those who challenge faulty patents